FDG PET/CT 用于晚期黑色素瘤一线伊匹木单抗联合纳武利尤单抗治疗期间肿瘤及全身免疫反应监测
回顾性分析 31 例晚期黑色素瘤患者一线纳武利尤单抗联合伊匹木单抗治疗,于治疗前后行 FDG PET/CT 并按 PERCIST 评估。最佳总缓解为完全代谢缓解 25 例(80%)、部分代谢缓解 3 例(10%)、进展性代谢病 3 例(10%);进展性代谢病患者治疗前全身代谢肿瘤体积显著更高(p=0.009)。中位随访 21.5 个月时 26 例(84%)存活,中位无进展生存与总生存未达到;FDG PET/CT 可检测临床相关免疫相关不良事件。
要点
- 一线联合免疫检查点抑制剂治疗后 FDG PET/CT 代谢缓解评估可预测长期结局。
- 进展性代谢病患者治疗前全身代谢肿瘤体积显著更高(p=0.009)。
- FDG PET/CT 常检出临床相关免疫相关不良事件,部分早于临床表现。
核心结论
- FDG PET/CT 代谢反应评估可预测一线联合免疫检查点抑制剂治疗晚期黑色素瘤患者的长期结局。
- FDG PET/CT 长期监测用于检出颅外继发进展是可行的。
- 除反应评估外,FDG PET/CT 常检出临床相关免疫相关不良事件,可同时或在不同时间点累及多个系统,并可早于临床诊断。
研究设计与样本
- 回顾性研究,纳入 2016 至 2018 年 31 例连续接受一线纳武利尤单抗联合伊匹木单抗治疗的晚期黑色素瘤患者。
- 患者需有治疗前及治疗后 FDG PET/CT(分别在开始免疫检查点抑制剂后 2 个月和 4 个月内完成),且至少一个病灶可按实体瘤 PET 反应标准(PERCIST)评估。
- 颅外反应通过每 3 个月 FDG PET/CT 监测;治疗前后测量全身代谢肿瘤体积(wbMTV)并与结局做相关性分析。
主要发现
- 患者中位年龄 60 岁(范围 30-78 岁);至首次治疗后 FDG PET/CT 反应评估的中位联合免疫检查点抑制剂周期数为 3(四分位距 2-4)。
- 最佳总缓解为完全代谢缓解 25 例(80%)、部分代谢缓解 3 例(10%)、进展性代谢病 3 例(10%)。
- 进展性代谢病患者治疗前 wbMTV 显著更高(p=0.009)。
- 中位随访 21.5 个月时 26 例(84%)存活,中位无进展生存与总生存未达到;9/31 例(29%)发生继发进展,中位时间 8.2 个月(四分位距 6.9-15.5),其中多数(78%)由 FDG PET/CT 检出。
- 治疗后 FDG PET/CT 提示免疫相关不良事件的 36 项发现中,29 项(80%)获临床确认;3 例(7%)FDG PET/CT 发现早于临床表现;最常见的可检出免疫相关不良事件为内分泌病(36%)和小肠结肠炎(35%)。
关键数值与推荐
- 颅外反应按 PERCIST 评估,最佳总缓解分为完全代谢缓解、部分代谢缓解和进展性代谢病。
- 免疫相关不良事件定义为治疗后 FDG PET/CT 上新出现的非肿瘤性摄取增高,并与临床表现做相关性分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We aimed to investigate the role of FDG-PET/CT in monitoring of response and immune-related adverse events (irAEs) following first-line combination-immune checkpoint inhibitor (combination-ICI) therapy for advanced melanoma. METHODS: We retrospectively reviewed outcomes in patients who had (1) first-line nivolumab plus ipilimumab; (2) pre- and post-treatment FDG-PET/CT scans (pre-FDG-PET/CT and post-FDG-PET/CT) within 2 and 4 months of starting ICI, respectively; and (3) at least one lesion assessable by PET response criteria in solid tumors (PERCIST). Extracranial response was monitored by 3 monthly FDG-PET/CT. Whole-body metabolic tumor volume (wbMTV) was measured pre- and post-treatment and correlated with outcome. FDG-PET/CT manifestations of irAE were defined as new increased non-tumoral uptake on post-FDG-PET/CT and were correlated with clinical presentation. RESULTS: Thirty-one consecutive patients, median age 60 years (range, 30-78), were identified from 2016 to 2018. The median number of combination-ICI cycles to the first post-FDG-PET/CT response assessment was 3 (interquartile range (IQR), 2-4). The best-overall responses were complete metabolic response (CMR) in 25 (80%), partial metabolic response (PMR) in 3 (10%), and progressive metabolic disease (PMD) in 3 (10%) patients. Patients with PMD had significantly higher pre-treatment wbMTV (p = 0.009). At a median follow-up of 21.5 months, 26 (84%) patients were alive with median progression-free and overall survival not reached. Secondary progression occurred in 9/31 (29%) patients at a median of 8.2 months (IQR, 6.9-15.5), of those majority (78%) was detected by FDG-PET/CT. Of 36 findings on post-FDG-PET/CT suggestive of irAE, 29 (80%) had clinical confirmation. In 3 (7%), the FDG-PET/CT findings preceded clinical presentation. The most common FDG-PET/CT detectable irAEs were endocrinopathies (36%) and enterocolitis (35%). CONCLUSION: FDG-PET/CT response evaluation predicts the long-term outcome of patients treated with first-line combination-ICIs. Long-term treatment response monitoring for detection of extracranial secondary progression is feasible by FDG-PET/CT. Beyond response assessment, FDG-PET/CT frequently detects clinically relevant irAEs, which may involve multiple systems contemporaneously or at various time-points and may precede clinical diagnosis.
引用
- Iravani A, Osman MM, Weppler AM, et al. FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging. 2020. PMID: 32338306. doi:10.1007/s00259-020-04815-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。